Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status

Most clinical trials of non‐small‐cell lung cancer (NSCLC) exclude patients with poor ECOG performance status (PS). Thus, the efficacy of immune checkpoint inhibitors (ICIs) in patients with poor PS remains unclear. Herein, we used data from a retrospective cohort to assess the potential clinical be...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Kano, Hirohisa, Ichihara, Eiki, Harada, Daijiro, Inoue, Koji, Kayatani, Hiroe, Hosokawa, Shinobu, Kishino, Daizo, Watanabe, Kazuhiko, Ochi, Nobuaki, Oda, Naohiro, Hara, Naofumi, Ninomiya, Kiichiro, Hotta, Katsuyuki, Maeda, Yoshinobu, Kiura, Katsuyuki
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Clinical Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7540975/
https://ncbi.nlm.nih.gov/pubmed/32726470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14590
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars